Roche has announced the commercial availability of the cobas HCV Genotyping (GT) assay for the hepatitis C virus in countries...
Novartis announced that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.
PTC Therapeutics, Inc. announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing...
Merck has announced that the company has submitted a New Drug Application to the FDA for grazoprevir/elbasvir (100mg/50mg), an investigational...
Merck Inc. announced that the FDA has approved Zepatier (elbasvir and grazoprevir) for the treatment of adult patients with chronic...
Abbott is initiating a US market withdrawal for the Trifecta family of valves and will be removing the limited remaining inventory from the field. On February 27, 2023, Abbott and the US FDA communicated the potential for early Structural Valve Deterioration (SVD) and provided patient management considerations for those patients implanted with the Trifecta and Trifecta GT valves. The assessment of incidence and risk associated with early SVD has not changed since the February communication.
GSK, Fondazione Telethon and Ospedale San Raffaele announced the publication in BLOOD of the long-term safety and efficacy data from...
The FDA has approved NovoSeven RT (Coagulation Factor VIIa [Recombinant]), from Novo Nordisk, as the first recombinant treatment for bleeding...
AbbVie announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...